Replies to post #112 on Alnylam Pharmaceuticals Inc (ALNY)

[surf1944]

8:45AM On The Wires (WIRES) :
Alnylam Pharmaceuticals (ALNY) announced that it has initiated dosing in its Phase I clinical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia.